Vice President, Business Development, Specialty Services

Position Summary

We have an opportunity for a Vice President, Business Development - Specialty Services to join our team. This role is responsible for driving profitable growth across micronization, spray drying, and inhalation technologies. You will lead global business development and strategic account management, ensuring commercial commitments deliver sustainable growth and long-term customer value. This position partners closely with cross-functional teams to align strategy, execution, and operational performance.

Location: Field Based (up to 50% travel)

The Role

Define and execute the global commercial strategy aligned with business plans and financial objectives.
Translate market demand and competitive dynamics into actionable growth priorities and account strategies.
Shape and refine the value proposition, focusing on lifecycle continuity, speed to clinic, and scalability.
Own and grow executive-level relationships with key biotech and pharmaceutical customers.
Lead and close complex, multi-year commercial agreements, including MSAs, SOWs, and long-term supply agreements.
Co-own pricing strategy and deal structures to meet growth and margin targets.
Ensure contracts balance competitiveness, feasibility, and profitability.
Oversee global sales pipeline governance and maintain disciplined operating cadence.
Partner with Operations, Quality, and Program Management to ensure commercial commitments are achievable.
Provide oversight for onboarding and governance of new customers and major expansions.
Collaborate on market intelligence and capacity planning to optimize growth.
Build and lead a high-performing global business development team with strong succession planning.
Establish a culture of accountability, collaboration, and disciplined execution.

The Candidate

Bachelor’s degree in a scientific or technical discipline; advanced degree such as Master of Science or Master of Business Administration preferred.
15+ years of progressive commercial leadership experience within contract development and manufacturing organizations, biopharma services, or related life sciences sectors.
Demonstrable leadership experience at Catalent (including but not limited to participation in Catalent‑sponsored leadership programs such as NGGL, GOLD, LEAD Now, GM Excellence, and GROW) may be considered in place of external experience.

Preferred Skills & Background

Experience with micronization, spray drying, and/or inhalation technologies preferred.

Pay:

The annual pay range for this position in New Jersey is $250,000-300,000

The annual pay range for this position in California is $250,000-300,000

The final salary offered to a successful candidate may vary, and will be dependent on several factors that may include but are not limited to: the type and length of experience within the job, type and length of experience within the industry, skillset, education, business needs, etc. Catalent is a multi-state employer, and this salary range may not reflect positions that work in other states.

Why you should Join Catalent

Join a high growth and fast paced organization with a people focused culture
Global exposure, defined career path and annual performance review and feedback process
Competitive Medical, Dental, Vision and 401K
26 days PTO & 8 paid holidays

Catalent offers rewarding opportunities to further your career! Join the global drug development and delivery leader and help us bring over 7,000 life-saving and life-enhancing products to patients around the world. Catalent is an exciting and growing international company where employees work directly with pharma, biopharma and consumer health companies of all sizes to advance new medicines from early development to clinical trials and to the market. Catalent produces more than 70 billion doses per year, and each one will be used by someone who is counting on us. Join us in making a difference.

personal initiative. dynamic pace. meaningful work.

Visit Catalent Careers to explore career opportunities.

Catalent is an Equal Opportunity Employer, including disability and veterans.

If you require reasonable accommodation for any part of the application or hiring process due to a disability, you may submit your request by sending an email, and confirming your request for an accommodation and include the job number, title and location to [email protected]. This option is reserved for individuals who require accommodation due to a disability. Information received will be processed by a U.S. Catalent employee and then routed to a local recruiter who will provide assistance to ensure appropriate consideration in the application or hiring process.

Notice to Agency and Search Firm Representatives: Catalent Pharma Solutions (Catalent) is not accepting unsolicited resumes from agencies and/or search firms for this job posting. Resumes submitted to any Catalent employee by a third party agency and/or search firm without a valid written & signed search agreement, will become the sole property of Catalent. No fee will be paid if a candidate is hired for this position as a result of an unsolicited agency or search firm referral. Thank you.

Important Security Notice to U.S. Job Seekers:

Catalent NEVER asks candidates to provide any type of payment, bank details, photocopies of identification, social security number or other highly sensitive personal information during the offer process, and we NEVER do so via email or social media. If you receive any such request, DO NOT respond— it is a fraudulent request. Please forward such requests to [email protected] for us to investigate with local authorities.

California Job Seekers can find our California Job Applicant Notice HERE.

Volunteer Work Disclosure: Applicants for employment in Massachusetts may include in their employment history any verified work performed on a volunteer basis.

Massachusetts Lie Detector Test Notice: It is unlawful in Massachusetts to require or administer a lie detector test as a condition of employment or continued employment. An employer who violates this law may be subject to criminal penalties and civil liability. Consistent with Massachusetts law, Catalent does not require or administer lie detector tests as a condition of employment or continued employment.

About the company

Catalent provides end-to-end development, manufacturing, clinical supply, and packaging services for pharmaceutical, biotechnology, and consumer health clients. It develops formulations, scales manufacturing, and delivers clinical and commercial materials through an integrated supply chain under long-term partnerships tailored to each project. It differentiates itself through a broad, fully integrated service offering, lasting client relationships, and a focus on efficiency across the development and supply chain, along with commitments to sustainability. Its goal is to help clients accelerate product development and commercialization while managing costs, quality, and environmental impact across the product lifecycle.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Franklin Township, New Jersey

Founded

1996

Get referred to Catalent

See people who can refer or advise you

Simplify's Take

What believers are saying

August 25, 2026 refinancing cut interest $100 million and lifted liquidity to $1.1 billion.
ALK, Nanoscope, and Elpida expanded Catalent partnerships in 2026.
Novo Holdings' backing funded debt markets' confidence and multi-year capacity investments.

What critics are saying

Catalent will close Gosselies, Belgium, eliminating about 150 jobs after January 2026.
FDA hit Bloomington, Indiana with Form 483 and OAI; Scholar Rock dropped it.
Persistent FDA findings and demand cuts can strand Catalent's gene-therapy network.

What makes Catalent unique

Catalent's Zydis platform secured ALK's September 30, 2026 capacity expansion.
Taysha named Catalent primary commercial manufacturer on August 3, 2026.
Nearly 40 global sites let Catalent span development, fill-finish, packaging.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance
Dental Insurance
Vision Insurance
401(k) Company Match
Paid Vacation
Paid Holidays
Tuition Reimbursement
Wellness Program

Company News

Catalent

Oct 15th, 2026

Alessandro Maselli joins industry leaders to celebrate biotech innovation and the future of healthcare at Endpoints 11.

Alessandro Maselli joins industry leaders to celebrate biotech innovation and the future of healthcare at Endpoints 11. Catalent President & CEO, Alessandro Maselli, recently joined biotechnology leaders to recognize eleven of the sector's most promising startups and founders at the 2026 Endpoints 11 Awards. Hosted by Endpoints News, the Endpoints 11 Awards recognize emerging biotechnology companies whose scientific innovation and bold vision are advancing the next generation of medicines and therapies. This annual event brings together industry leaders, investors and scientists to celebrate excellence and recognize the companies helping drive the future of healthcare. In his welcome remarks, Alessandro addressed the forces reshaping the environment for biotech, including emerging science, changing investment conditions, evolving global development pathways and the impact of AI. He highlighted the importance of moving with speed, engaging the right partners early and keeping patients at the center of decision-making. His remarks reinforced Catalent's longstanding commitment to partnering with innovators as they advance promising therapies to patients. View the 2026 Endpoints 11 Awards ceremony on the Endpoints News website: https://events.endpoints.news/eleven26

Contract Pharma

Oct 5th, 2026

Catalent launches accelerated gene-to-drug substance program in US for complex biologics.

Catalent launches accelerated gene-to-drug substance program in US for complex biologics. The program is designed to help developers move next-gen molecules from gene sequence to drug substance in 10 months. October 5, 2026 Content Marketing Editor Editor's Take: As biologic pipelines shift toward more complex formats, accelerated programs can give developers a more predictable path forward. Catalent is launching an accelerated gene-to-drug substance program in the United States for complex molecules, namely biologics. The company says the offering complements its drug substance and drug product capabilities. The program helps developers move bispecifics, multispecifics, and other next-generation molecules from gene sequence to drug substance in 10 months. This includes later steps in the path including from bulk drug substance to fill-finish readiness. Biologics building blocks. Catalent says this builds on its Rapid Antibody offering, for traditional monoclonal antibodies (mAbs). This supports gene-to-GMP (good manufacturing practice) drug substance in as few as eight months. "For patients facing serious conditions, faster access to advanced biologics can be critical." David McErlane, Catalent Biologics Group President According to Catalent, biologic pipelines are shifting toward more complex formats. That being the case, accelerated programs can give developers a more predictable path from early development to clinical supply. Catalent's program combines its GPEx Lightning cell line development technology with integrated development and manufacturing workflows. Adding in U.S.-based execution, Catalent says it can bring complex biologics along at a speed usually associated with standard mAbs. Outline of Catalent process milestones. Specifically, Catalent's timeline for complex biologics involves three customer-facing milestones from gene sequence. Master cell bank conditional release is anticipated by month seven. Following this - bulk drug substance shipments to Catalent by month nine, and bulk drug substance lot release by month 10. "For patients facing serious conditions, faster access to advanced biologics can be critical," Catalent Biologics Group President David McErlane said. "Catalent is helping customers move complex antibodies through a defined, disciplined path to the clinic." A global CDMO, Catalent employs thousands of scientists and technicians at nearly 40 sites worldwide. Add us as a preferred source on Google. Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

GlobeNewswire

Sep 30th, 2026

ALK expands strategic tablet supply partnership with Catalent.

ALK expands strategic tablet supply partnership with Catalent. September 30, 2026 09:03 ET | Source: ALK Abello Inside Information * Agreement provides long-term expanded access to Catalent's fast-dissolving (Zydis(R) tablet formulation technology. * Supply robustness secured with prioritised manufacturing capacity increase of ~40% to 1.1 billion tablets annually from early 2030s. * Over three years, ALK to invest DKK 500 million in capacity at Catalent. ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that it has expanded its long-standing contract manufacturing partnership with Catalent, Inc. ("Catalent"), a leader in enabling the development and supply of better treatments for patients worldwide. Establishing long-term supply robustness is a strategic priority for ALK, and the expanded agreement secures ALK long-term access to Catalent's Zydis(R) technology for all its allergen products, including potential future tablets for peanut and tree nut allergies. The agreement also secures additional production capacity to sustain the expected future demand for ALK's SLIT (sublingual immunotherapy) tablet portfolio. Based on production sites in the UK and Canada, ALK expects to increase its annual tablet capacity by an additional 300 million to 1.1 billion tablets from early 2030s and beyond. Peter Halling, President & CEO, said: "We are very pleased to reinforce our long-standing collaboration with Catalent, which plays an important role in producing ALK's SLIT tablets. This partnership, already in place for more than two decades, has the potential to become one of the longest lasting in pharma. The expanded partnership underscores the unique durability of our core business model - with no patent cliff to manage - while the strengthened supply chain and added capacity secure our ability to serve many more people with allergy for years to come." Terms and financials Under the terms of the agreement, ALK will commit total payments to Catalent of approximately DKK 500 million to secure the capacity expansion. These payments will be capitalised over three years on the balance sheet under 'prepayments' and amortised over the duration of the contract. The development in future manufacturing costs is expected to offset these initial payments over time. The agreement does not affect ALK's financial guidance for 2026 or ALK's long-term financial targets. ALK-Abelló A/S For further information please contact: Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525 Media: Maiken Riise Andersen, tel. +45 5054 1434 This announcement contains inside information. This is information that ALK-Abelló A/S is obliged to make public pursuant to the EU Market Abuse Regulation. About ALK ALK is a global specialty pharmaceutical company focused on allergy. ALK's activities cover the entire value chain of developing, sourcing, producing, and marketing a diversified portfolio of products for diagnosing and treating respiratory allergies and severe allergic reactions (anaphylaxis) in both children and adults. Headquartered in Denmark, ALK employs around 2,800 people worldwide and is listed on Nasdaq Copenhagen (Nasdaq: ALK B). Visit us at www.alk.net. About Catalent Catalent, Inc. is a leading global contract development and manufacturing organisation (CDMO) delivering tailored, end-to-end solutions across all phases of development and manufacturing for pharma, biotech and consumer health customers, and supplying billions of doses annually from nearly 40 global sites. Among its proprietary technologies is Zydis(R)[,] a freeze-dried orally disintegrating tablet formulation that disperses almost instantly in the mouth, offering a fast, convenient and palatable dosage form - particularly suited to patients, such as children, who may struggle with conventional tablets.

Pharma Manufacturing

Sep 10th, 2026

Catalent secures $4.7B refinancing to expand biologics and oral drug capacity

Catalent has completed a debt refinancing transaction to enhance its financial flexibility and expand capacity in high-demand areas. The deal includes a new $4.1 billion seven-year Term Loan B facility and a $600 million revolving credit facility, expected to reduce annual interest expenses by approximately $100 million. The CDMO plans to invest in its Zydis orally disintegrating tablet platform and expand domestic biologics manufacturing, including larger-scale bioreactor capacity at its Madison site. The company is also capitalising on US onshoring trends by expanding domestic capacity. The refinancing follows Novo Holdings' $16.5 billion acquisition of Catalent in 2023, with plans to double the company's size over five years. Catalent now has approximately $1.1 billion in available liquidity.

GlobeNewswire

Sep 10th, 2026

Ritedose appoints Carolyn Berg as new Vice President of Strategic Growth.

Ritedose appoints Carolyn Berg as new Vice President of Strategic Growth. The role will focus on identifying new opportunities and strengthening existing customer relationships to accelerate Ritedose's continued growth. COLUMBIA, S.C., Sept. 10, 2026 (GLOBE NEWSWIRE) - The Ritedose Corporation (Ritedose), the largest contract development and manufacturing organization (CDMO) in the United States specializing in sterile Blow-Fill-Seal (BFS) production of unit-dose solutions for the ophthalmic and respiratory markets, today announced the appointment of Carolyn Berg as the company's Vice President of Strategic Growth. Berg brings more than 25 years of domestic and international experience in marketing, sales and business development. Prior to joining Ritedose, Berg served as Vice President of Business Development for Catalent's inhaled drug delivery solutions, where she led commercial strategy and global sales efforts to expand the company's inhalation business. Earlier in her career, she held leadership roles at Cipla, Teva Respiratory and Merck, building extensive experience in business development, portfolio strategy, strategic marketing, product commercialization and commercial leadership. "As Ritedose continues to expand its capabilities and position itself for the next phase of growth, Carolyn's leadership will be instrumental in identifying new opportunities and ensuring our growth remains centered on the customers and patients we serve," said Jody Chastain, President and CEO of Ritedose. "Carolyn brings a tremendous depth of commercial experience, a proven understanding of the pharmaceutical markets we serve, and a collaborative approach to leadership." In her new role, Berg will advance Ritedose's commercial strategy, strengthen relationships with existing customers and identify new opportunities to support the company's continued growth in the inhalation and ophthalmic markets, as well as future market expansions. The appointment reflects Ritedose's continued growth and strategic investment in its leadership, infrastructure and capabilities needed to accelerate the Company into its next chapter. "Ritedose has built an impressive platform for delivering high-quality sterile medicines, and I'm excited to join the company at such an important inflection point in its growth trajectory," said Berg. "There is a significant opportunity to build on Ritedose's strengths in ophthalmic and respiratory manufacturing while deepening our relationships with existing customers and developing new strategic partnerships. I look forward to working with my Ritedose colleagues to identify opportunities that create value for our customers and help bring safe and high-quality therapeutics to patients who need them." Berg earned bachelor's degrees in Journalism/ Public Relations and French from the University of Texas at Austin and an International MBA from the Darla Moore School of Business at the University of South Carolina. About The Ritedose Corporation Ritedose is the largest sterile contract development manufacturing organization (CDMO) in the US specializing in sterile Blow Fill Seal (BFS) technology that ensures sterile, consistent, and safe unit dose delivery. The company's process guides pharmaceutical partners from pre-IND and CMC development through commercialization of branded and generic inhalation and ophthalmic medications. of branded and generic inhalation and ophthalmic medications. With a focus on quality, innovation, and customer satisfaction, Ritedose partners with leading pharmaceutical companies to deliver safe, effective, and reliable medications that improve patient outcomes. For more information about Ritedose and its services: visit Ritedose.com. Media Contact Alex Keown Inspire Agency on behalf of Ritedose [email protected] 630-346-5141

Catalent

Vice President, Business Development, Specialty Services

About the job